Ixabepilone, a novel epothilone analog in the treatment of breast cancer. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Expert Opinion on Investigational Drugs Année : 2008

Ixabepilone, a novel epothilone analog in the treatment of breast cancer.

Résumé

BACKGROUND: Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing cell death. Ixabepilone (BMS-247550, Ixempra) is an epothilone analog that optimizes the properties naturally observed with epothilone B. OBJECTIVE: To provide an overview of the results achieved by ixabepilone in metastatic breast cancer. METHODS: A PubMed search was performed to provide an extensive review of all published data on ixabepilone, in addition to all data reported from international congresses, from 2003 to 2007. RESULTS/CONCLUSION: There is a clear need for new agents active against resistant metastatic breast cancer and ixabepilone might be a welcome new compound in this situation.

Domaines

Immunologie
Fichier non déposé

Dates et versions

inserm-00483392 , version 1 (14-05-2010)

Identifiants

Citer

Xavier B. Pivot, Christian Villanueva, Loïc Chaigneau, Thierry Nguyen, Martin Demarchi, et al.. Ixabepilone, a novel epothilone analog in the treatment of breast cancer.. Expert Opinion on Investigational Drugs, 2008, 17 (4), pp.593-9. ⟨10.1517/13543784.17.4.593⟩. ⟨inserm-00483392⟩

Collections

INSERM UNIV-FCOMTE
51 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More